Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 2/20 | 0.43 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 5/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 6/20 | 0.39 |
| ▸ | ATM | Q13315 | 3/20 | 0.38 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3097370 | 0.87 | NPC1 (0.51) | LARS1 | |
| Hydrochloric Acid SCHEMBL3101058 | 0.86 | NPC1 (0.50) | LARS1 | |
| SCHEMBL3096098 | 0.86 | LARS1 (0.45) | LARS1F2PLG | |
| SCHEMBL3096503 | 0.86 | LARS1 (0.45) | LARS1F2PLG | |
| SCHEMBL3097672 | 0.86 | RAB9A (0.53) | LARS1 | |
| SCHEMBL3093732 | 0.85 | LARS1 (0.44) | LARS1F2PLG | |
| SCHEMBL3102970 | 0.85 | MMP9 (0.46) | LARS1F2PLG | |
| SCHEMBL3093901 | 0.85 | MMP9 (0.46) | LARS1F2PLG | |
| Hydrochloric Acid SCHEMBL3089133 | 0.85 | SMN1; SMN2 (0.45) | LARS1F2 | |
| SCHEMBL3079484 | 0.84 | NPC1 (0.46) | LARS1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | VCP 905/4885LARS1 1976/4885ATR 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.